Iroprem

Ferric Carboxymaltose, the active ingredient in Iroprem, is an iron supplement presented as an intravenous solution for intravenous use. It is indicated for the treatment of iron deficiency anemia, including anemia associated with chronic kidney disease and anemia resulting from gastrointestinal blood loss, providing rapid replenishment of iron stores in patients who cannot tolerate oral iron.

GNH USA supplies Iroprem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics globally worldwide, with distribution aligned to EU regulatory standards.

Iroprem is used to treat iron deficiency anemia and related conditions by restoring iron stores.

Iron deficiency anemia: restores hemoglobin levels and improves symptoms of fatigue and weakness. Anemia associated with chronic kidney disease: provides intravenous iron to patients on dialysis or with reduced renal function, supporting erythropoiesis. Anemia due to gastrointestinal blood loss: replenishes iron lost through chronic bleeding, aiding recovery of normal red blood cell production.

Iroprem may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypersensitivity reactions: mild rash, pruritus, flushing. - Nausea: transient feeling of sickness. - Headache: mild to moderate.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hypotension: sudden drop in blood pressure during infusion. - Iron overload: excessive iron accumulation if dosing exceeds needs.

When using Iroprem, clinicians should observe several safety measures.

Monitor iron parameters: check serum ferritin and transferrin saturation before and during therapy. Assess for hypersensitivity: observe patient during infusion for signs of reaction. Avoid rapid infusion: administer over the recommended time to reduce risk of hypotension. Use caution in patients with active infection: iron may promote bacterial growth. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iroprem can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other intravenous iron products: risk of iron overload. - Concurrent administration with erythropoiesis‑stimulating agents without iron monitoring: may exacerbate hypertension.

Moderate Interactions (Monitor Closely): - Oral iron supplements: may reduce absorption of ferric carboxymaltose if given simultaneously; separate dosing times. - Antacids containing aluminum or magnesium: can interfere with iron binding; monitor levels. - Chelating agents (e.g., deferoxamine): may bind administered iron and reduce efficacy.